von Bubnoff N - Search Results

1

The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System.

Gebauer N, Ziehm M, Gebauer J, Riecke A, Meyhöfer S, Kulemann B, von Bubnoff N, Steinestel K, Bauer A, Witte HM. Gebauer N, et al. Among authors: von bubnoff n. Cancers (Basel). 2022 Nov 7;14(21):5465. doi: 10.3390/cancers14215465. Cancers (Basel). 2022. PMID: 36358883 Free PMC article.

2

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.

von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J. von Bubnoff N, et al. Cell Cycle. 2005 Mar;4(3):400-6. doi: 10.4161/cc.4.3.1560. Epub 2005 Mar 25. Cell Cycle. 2005. PMID: 15738656 Review.

3

Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction.

Ott I, Keller U, Knoedler M, Götze KS, Doss K, Fischer P, Urlbauer K, Debus G, von Bubnoff N, Rudelius M, Schömig A, Peschel C, Oostendorp RA. Ott I, et al. Among authors: von bubnoff n. FASEB J. 2005 Jun;19(8):992-4. doi: 10.1096/fj.04-3219fje. Epub 2005 Apr 6. FASEB J. 2005. PMID: 15814609

4

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.

von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. von Bubnoff N, et al. Leukemia. 2005 Sep;19(9):1670-1. doi: 10.1038/sj.leu.2403887. Leukemia. 2005. PMID: 16015383 No abstract available.

5

Chronic myelogenous leukemia: treatment and monitoring.

von Bubnoff N, Duyster J. von Bubnoff N, et al. Dtsch Arztebl Int. 2010 Feb;107(7):114-21. doi: 10.3238/arztebl.2010.0114. Epub 2010 Feb 19. Dtsch Arztebl Int. 2010. PMID: 20221270 Free PMC article. Review.

6

Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose.

Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, Avril N. Sandherr M, et al. Among authors: von schilling c, von bubnoff n. Ann Oncol. 2001 May;12(5):719-22. doi: 10.1023/a:1011136324038. Ann Oncol. 2001. PMID: 11432634 Free article.

7

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.

Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N. Illert AL, et al. Among authors: von bubnoff n. PLoS One. 2014 Nov 26;9(11):e112318. doi: 10.1371/journal.pone.0112318. eCollection 2014. PLoS One. 2014. PMID: 25426931 Free PMC article.

8

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.

Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J. Kancha RK, et al. Among authors: von bubnoff n. Haematologica. 2008 Nov;93(11):1718-22. doi: 10.3324/haematol.13207. Epub 2008 Aug 25. Haematologica. 2008. PMID: 18728023 Free article.

9

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.

von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. von Bubnoff N, et al. Leukemia. 2005 Feb;19(2):286-7. doi: 10.1038/sj.leu.2403600. Leukemia. 2005. PMID: 15618966 No abstract available.

10

Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.

Lier A, Penzel R, Heining C, Horak P, Fröhlich M, Uhrig S, Budczies J, Kirchner M, Volckmar AL, Hutter B, Kreutzfeldt S, Endris V, Richter D, Wolf S, Pfütze K, Neumann O, Buchhalter I, Morais de Oliveira CM, Singer S, Leichsenring J, Herpel E, Klauschen F, Jost PJ, Metzeler KH, Schulze-Osthoff K, Kopp HG, Kindler T, Rieke DT, Lamping M, Brandts C, Falkenhorst J, Bauer S, Schröck E, Folprecht G, Boerries M, von Bubnoff N, Weichert W, Brors B, Lichter P, von Kalle C, Schirmacher P, Glimm H, Fröhling S, Stenzinger A. Lier A, et al. Among authors: von kalle c, von bubnoff n. JCO Precis Oncol. 2018 Nov;2:1-13. doi: 10.1200/PO.18.00171. JCO Precis Oncol. 2018. PMID: 35135162

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page